Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

Selected as best IPO in 2019

FluoGuide won the 2019 share price development award in the micro-cap category and also received the honorary quality award (Affärsvärlden’s IPO Guide).

First patient enrolled in the phase I/II clinical trial testing FG001 in patients with high grade glioma

Press release


November 9, 2020

Copenhagen, Denmark, 9 November 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to inform that the first patient today was enrolled in the clinical trial testing safety and efficacy of FG001 in guiding high grade glioma surgery.

FluoGuide’s phase I/II clinical trial, testing FG001 in patients with high grade glioma consists of two phases; (1) a dose escalation phase to establish safety and proof-of-concept, and (2) an efficacy assessment phase. The total number of patients in the entire phase I/II trial will be up to 36 patients.

FluoGuide is pleased to inform that the first patient has now been enrolled in the dose escalation phase of the clinical trial. The results will be evaluated and made available as earlier communicated in the Company’s interim report from second quarter, published in August 2020. The interim report is available on FluoGuides website www.fluoguide.com.